Developer docs
API playgroundTry for free, no card

Search company profiles

OncoBeta

Full company profile

uuid000aotf

Namestring
OncoBeta
Legal namestring
OncoBeta GmbH
Websiteurl
oncobeta.com
Company typeenum
Private
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGarching Bei München, Germany
HQ citystring
Garching Bei München
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epidermal radioisotope therapy, non-melanoma skin cancer treatment, rhenium-188 brachytherapy, medical device manufacturing, radioisotope generator production
Industry1 code
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Irradiation Apparatus Manufacturing334517
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Biological Products, (No Disgnostic Substances)2836
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Radiation Therapy Medical Devices
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Rhenium-SCT Therapy System
TypeHardware Sales
Description

OncoBeta generates revenue through the sale of their Rhenium-SCT medical device system, including the applicator, Rhenium-188 compound carpules, and related consumables used in skin cancer treatment procedures at certified healthcare facilities.

oncobeta.com
2188W/188Re Generators
TypeHardware Sales
Description

Sale of Tungsten-188/Rhenium-188 generators for commercial production of Rhenium-188 radioisotope, used both by OncoBeta and potentially other facilities for various therapeutic applications.

oncobeta.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OncoBeta develops, manufactures, and sells the Rhenium-SCT (Skin Cancer Therapy) system, a proprietary epidermal radioisotope brachytherapy that uses the Rhenium-188 beta emitter for non-invasive treatment of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma). The integrated offering includes the 188W/188Re generator, the Rhenium-188 compound in prefilled carpules, and a shielded applicator device, sold to certified healthcare facilities that administer the single-session painless treatment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 98.5% complete remission rate in several studies
+3 more records
Product overview1 text field

OncoBeta offers a portfolio of medical devices and radioisotope products for non-melanoma skin cancer treatment. The core offering is the Rhenium-SCT® system, which consists of the 188W/188Re Generator (producing the therapeutic Rhenium-188 radioisotope), the Rhenium-188 Compound (the therapeutic formulation), and the OncoBeta® Applicator (the delivery device). These components work together as an integrated brachytherapy solution: the generator produces the radioisotope, which is formulated into a compound, and applied to skin cancer lesions using the applicator in a single painless session.

Product and service4 records
1Rhenium-SCT (Skin Cancer Therapy)
CategoryEpidermal Radioisotope Brachytherapy
Description

A specialized state-of-the-art brachytherapy utilizing the beta-emitter radioisotope Rhenium-188 for the painless, non-invasive, single-session treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin. Provides positive aesthetic outcomes without invasive surgery. Sold to and administered by certified healthcare facilities.

2188W/188Re Generator
CategoryRadioisotope Generator Systems
Description

Tungsten-188/Rhenium-188 generator system for commercial production of high-energy beta-emitting Rhenium-188. Available in sizes up to 150GBq (4Ci) with high activity concentration up to 9GBq/ml, variable elution volume of 5-14 ml, and low 188W breakthrough. Supplies the radioisotope used by OncoBeta's Rhenium-SCT therapy.

3OncoBeta Applicator
CategoryMedical Device / Applicator
Description

A specially designed medical device that applies the Rhenium-188 compound with a brush homogeneously over the lesion to be treated. Features integrated shielding material for optimal radiation protection of both physician and patient. Component of the Rhenium-SCT system.

4Rhenium-188 Compound (Prefilled Carpules)
CategoryRadioactive Compound / Consumable
Description

A specialized liquid plastic compound binding Rhenium-188 for precise, mechanical-dose application over tumors. Supplied in pre-manufactured carpules that are loaded into the OncoBeta Applicator for safe handling and efficient use in each treatment procedure.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Sirtex Medical
TypeDirect peer
Description

Sirtex develops SIR-Spheres Y-90 resin microspheres for radioembolization of liver tumors. Comparable to OncoBeta as a therapeutic radiopharma company applying targeted internal radiation to solid tumors, with similar commercial-stage profile and direct-to-hospital sales model.

2Elekta
TypeBroad incumbent
Description

Elekta is a leading manufacturer of radiation therapy and radiosurgery equipment (linear accelerators, brachytherapy afterloaders) used to treat cancer. Comparable to OncoBeta in the broader radiation oncology space, though Elekta competes primarily with external beam radiotherapy rather than targeted isotope therapy.

3Novartis
TypeBroad incumbent
Description

Novartis operates the leading therapeutic radiopharmaceutical franchise (Pluvicto, Lutathera) through its Advanced Accelerator Applications subsidiary. Comparable to OncoBeta as a therapeutic radiopharma company using targeted radionuclides, but vastly larger and focused on prostate cancer and neuroendocrine tumors rather than NMSC.

4Philips (Radiation Oncology / Therapy)
TypeBroad incumbent
Description

Philips provides imaging-guided radiation therapy and oncology informatics solutions to hospitals globally. Comparable as a large healthcare incumbent serving cancer treatment infrastructure, with potential overlap at the hospital nuclear medicine and radiotherapy interface where OncoBeta's technology is deployed.

5Varian Medical Systems (Siemens Healthineers)
TypeBroad incumbent
Description

Varian is a global leader in radiation oncology hardware and software (TrueBeam, Eclipse, Halcyon). Comparable to OncoBeta as a radiation-based cancer treatment provider to hospitals, though Varian operates at much greater scale and across a broader oncology portfolio.

6Telix Pharmaceuticals
TypeDirect peer
Description

Telix develops diagnostic and therapeutic radiopharmaceuticals using targeted isotopes. Closely comparable to OncoBeta in business model (radiopharma development, isotope production, clinical oncology focus) and stage, though Telix is publicly listed and larger, with Illuccix for prostate cancer imaging and a growing therapeutic pipeline.

7Bracco Imaging
TypeBroad incumbent
Description

Bracco is a global imaging and radiopharmaceutical company with a broad portfolio including diagnostic agents and contrast media. Comparable to OncoBeta as a radiochemistry-based healthcare company, though Bracco is far larger and more diversified across diagnostic imaging.

8ITM Isotope Technologies Munich
TypeDirect peer
Description

ITM is a German-based radiopharmaceutical company producing therapeutic and diagnostic radioisotopes, including lutetium-177. Highly comparable to OncoBeta as a European radiopharma peer focused on targeted radionuclide therapy, with similar production and clinical development infrastructure.

9Bayer (Radiopharmaceuticals)
TypeBroad incumbent
Description

Bayer markets Xofigo (radium-223) for metastatic castration-resistant prostate cancer, one of the established therapeutic radiopharmaceutical franchises. Comparable in therapeutic radioisotope focus but operates as a broad incumbent within Bayer's larger pharmaceutical portfolio rather than a niche oncology specialist.

10Lantheus Holdings
TypeBroad incumbent
Description

Lantheus is a radiopharmaceutical-focused company with diagnostic imaging agents (e.g., Pylarify for PSMA PET) and a growing therapeutic pipeline. Comparable as a radiopharma specialist serving oncology, though more diagnostic-skewed and significantly larger than OncoBeta.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OncoBeta

Radiation Therapy Medical Devicesoncobeta.com

OncoBeta firmographics

Firmographics
Name
OncoBeta
Legal name
OncoBeta GmbH
Website
https://oncobeta.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

OncoBeta industry classification

Industry
Product category
Radiation Therapy Medical Devices
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Irradiation Apparatus Manufacturing (334517), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Epidermal radioisotope therapy
  • Non-melanoma skin cancer treatment
  • Rhenium-188 brachytherapy
  • Medical device manufacturing
  • Radioisotope generator production

Where OncoBeta is headquartered

Location

Headquarters

HQ city
Garching Bei München
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

OncoBeta business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Rhenium-SCT Therapy System: OncoBeta generates revenue through the sale of their Rhenium-SCT medical device system, including the applicator, Rhenium-188 compound carpules, and related consumables used in skin cancer treatment procedures at certified healthcare facilities.
  2. 188W/188Re Generators: Sale of Tungsten-188/Rhenium-188 generators for commercial production of Rhenium-188 radioisotope, used both by OncoBeta and potentially other facilities for various therapeutic applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

OncoBeta product offering

Product offering

Core offering

OncoBeta develops, manufactures, and sells the Rhenium-SCT (Skin Cancer Therapy) system, a proprietary epidermal radioisotope brachytherapy that uses the Rhenium-188 beta emitter for non-invasive treatment of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma). The integrated offering includes the 188W/188Re generator, the Rhenium-188 compound in prefilled carpules, and a shielded applicator device, sold to certified healthcare facilities that administer the single-session painless treatment.

Product overview

OncoBeta offers a portfolio of medical devices and radioisotope products for non-melanoma skin cancer treatment. The core offering is the Rhenium-SCT® system, which consists of the 188W/188Re Generator (producing the therapeutic Rhenium-188 radioisotope), the Rhenium-188 Compound (the therapeutic formulation), and the OncoBeta® Applicator (the delivery device). These components work together as an integrated brachytherapy solution: the generator produces the radioisotope, which is formulated into a compound, and applied to skin cancer lesions using the applicator in a single painless session.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rhenium-SCT (Skin Cancer Therapy) A specialized state-of-the-art brachytherapy utilizing the beta-emitter radioisotope Rhenium-188 for the painless, non-invasive, single-session treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin. Provides positive aesthetic outcomes without invasive surgery. Sold to and administered by certified healthcare facilities.
  • 188W/188Re Generator Tungsten-188/Rhenium-188 generator system for commercial production of high-energy beta-emitting Rhenium-188. Available in sizes up to 150GBq (4Ci) with high activity concentration up to 9GBq/ml, variable elution volume of 5-14 ml, and low 188W breakthrough. Supplies the radioisotope used by OncoBeta's Rhenium-SCT therapy.
  • OncoBeta Applicator A specially designed medical device that applies the Rhenium-188 compound with a brush homogeneously over the lesion to be treated. Features integrated shielding material for optimal radiation protection of both physician and patient. Component of the Rhenium-SCT system.
  • Rhenium-188 Compound (Prefilled Carpules) A specialized liquid plastic compound binding Rhenium-188 for precise, mechanical-dose application over tumors. Supplied in pre-manufactured carpules that are loaded into the OncoBeta Applicator for safe handling and efficient use in each treatment procedure.

Quantifiable outcome

  • 98.5% complete remission rate in several studies
  • +3 more outcomes

Companies that use OncoBeta

Customer profile

Named customers12 records

Segments3 records

Ideal customer profiles1 record

OncoBeta technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

OncoBeta partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

OncoBeta competitors and assessment

Company assessment

Direct peers

  • Sirtex Medical: Sirtex develops SIR-Spheres Y-90 resin microspheres for radioembolization of liver tumors. Comparable to OncoBeta as a therapeutic radiopharma company applying targeted internal radiation to solid tumors, with similar commercial-stage profile and direct-to-hospital sales model.
  • Telix Pharmaceuticals: Telix develops diagnostic and therapeutic radiopharmaceuticals using targeted isotopes. Closely comparable to OncoBeta in business model (radiopharma development, isotope production, clinical oncology focus) and stage, though Telix is publicly listed and larger, with Illuccix for prostate cancer imaging and a growing therapeutic pipeline.
  • ITM Isotope Technologies Munich: ITM is a German-based radiopharmaceutical company producing therapeutic and diagnostic radioisotopes, including lutetium-177. Highly comparable to OncoBeta as a European radiopharma peer focused on targeted radionuclide therapy, with similar production and clinical development infrastructure.

Broad incumbents

  • Elekta: Elekta is a leading manufacturer of radiation therapy and radiosurgery equipment (linear accelerators, brachytherapy afterloaders) used to treat cancer. Comparable to OncoBeta in the broader radiation oncology space, though Elekta competes primarily with external beam radiotherapy rather than targeted isotope therapy.
  • Novartis: Novartis operates the leading therapeutic radiopharmaceutical franchise (Pluvicto, Lutathera) through its Advanced Accelerator Applications subsidiary. Comparable to OncoBeta as a therapeutic radiopharma company using targeted radionuclides, but vastly larger and focused on prostate cancer and neuroendocrine tumors rather than NMSC.
  • Philips (Radiation Oncology / Therapy): Philips provides imaging-guided radiation therapy and oncology informatics solutions to hospitals globally. Comparable as a large healthcare incumbent serving cancer treatment infrastructure, with potential overlap at the hospital nuclear medicine and radiotherapy interface where OncoBeta's technology is deployed.
  • Varian Medical Systems (Siemens Healthineers): Varian is a global leader in radiation oncology hardware and software (TrueBeam, Eclipse, Halcyon). Comparable to OncoBeta as a radiation-based cancer treatment provider to hospitals, though Varian operates at much greater scale and across a broader oncology portfolio.
  • Bracco Imaging: Bracco is a global imaging and radiopharmaceutical company with a broad portfolio including diagnostic agents and contrast media. Comparable to OncoBeta as a radiochemistry-based healthcare company, though Bracco is far larger and more diversified across diagnostic imaging.
  • Bayer (Radiopharmaceuticals): Bayer markets Xofigo (radium-223) for metastatic castration-resistant prostate cancer, one of the established therapeutic radiopharmaceutical franchises. Comparable in therapeutic radioisotope focus but operates as a broad incumbent within Bayer's larger pharmaceutical portfolio rather than a niche oncology specialist.
  • Lantheus Holdings: Lantheus is a radiopharmaceutical-focused company with diagnostic imaging agents (e.g., Pylarify for PSMA PET) and a growing therapeutic pipeline. Comparable as a radiopharma specialist serving oncology, though more diagnostic-skewed and significantly larger than OncoBeta.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

OncoBeta social profiles

Digital presence

OncoBeta compliance and trust

Trust signal

Compliance3 records

OncoBeta financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OncoBeta leadership team

Management profile

Number of profiles

Profiles1 record

OncoBeta funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OncoBeta M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OncoBeta

What does OncoBeta do?

OncoBeta develops, manufactures, and sells the Rhenium-SCT (Skin Cancer Therapy) system, a proprietary epidermal radioisotope brachytherapy that uses the Rhenium-188 beta emitter for non-invasive treatment of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma). The integrated offering includes the 188W/188Re generator, the Rhenium-188 compound in prefilled carpules, and a shielded applicator device, sold to certified healthcare facilities that administer the single-session painless treatment.

Is OncoBeta a public or private company?

OncoBeta is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OncoBeta founded?

OncoBeta was founded in 2011. It employs 11 to 50 people.

Where is OncoBeta based?

OncoBeta is headquartered in Garching Bei München, Germany, in the Europe region.

How does OncoBeta make money?

Two revenue lines are on record. Rhenium-SCT Therapy System is the primary driver. The others are 188W/188Re Generators.

Who are OncoBeta's main competitors?

Direct peers on record are Sirtex Medical, Telix Pharmaceuticals and ITM Isotope Technologies Munich. Broad incumbents are Elekta, Novartis, Philips (Radiation Oncology / Therapy), Varian Medical Systems (Siemens Healthineers), Bracco Imaging, Bayer (Radiopharmaceuticals) and Lantheus Holdings.

Does OncoBeta have an API?

No public API is recorded for OncoBeta.

What industry is OncoBeta in?

OncoBeta's product category is Radiation Therapy Medical Devices. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 325414 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOncoBeta announces the expansion of Rhenium-SCT for non-melanoma skin cancer patients in ItalyOncoBeta, a medical device company headquartered in Germany, announced the expansion of its Rhenium-SCT (Skin Cancer Therapy) treatment services to Bolzano Hospital in Italy, marking a significant advancement in non-melanoma skin cancer treatment options in the country. The treatment, a painless single-session non-invasive radionuclide therapy using rhenium-188, will be provided to patients through OncoBeta's distribution partner DSD Pharma, with projected NMSC cases in Italy rising from 29,000 to 41,700 between 2022 and 2045. Rhenium-SCT is currently available across Germany, Austria, Switzerland, Italy, Spain, United Kingdom, South Africa, and Australia.PR NewswireLatest study demonstrates high efficacy in curing invasive non-melanoma skin cancerA clinical study conducted by researchers in Germany and funded by OncoBeta GmbH found that topical rhenium-188 skin cancer therapy is a highly effective treatment for non-melanoma skin cancer (NMSC), achieving a 97.5% response rate at 12 months with 95% complete responses across 40 lesions in 22 patients. The therapy demonstrated favorable cosmetic outcomes, particularly on the head and face, with no adverse events reported during application and most patients not experiencing adverse events during the trial period. Researchers suggest the treatment may be suitable for large tumors or those located on sensitive areas such as the nose, ear, or lips where surgery would be challenging.PR NewswireSouth African skin cancer patients undergo first treatments with OncoBeta's Rhenium-SCT as part of the EPIC-Skin studyOncoBeta GmbH announced that Steve Biko Academic Hospital in Pretoria, South Africa, has begun treating the first South African patients with its Rhenium-SCT therapy as part of the global phase IV EPIC-Skin study, making it the first South African facility to join the trial. The international study will monitor 210 adult patients over 24 months, with additional study centres located in Australia, Austria, the United Kingdom, and Germany, evaluating the efficacy, quality of life, and cosmetic outcomes of the non-invasive skin cancer treatment. South Africa has the highest prevalence of non-melanoma skin cancer (NMSC) on the African continent, where it ranks as the fifth-most diagnosed cancer, underscoring the clinical significance of expanding the trial to this region.PR Newswire'Spot Detective' - Check your spots this summerOncoBeta GmbH has launched The Spot Detective campaign across Australia to encourage Australians to get their skin checked for skin cancer ahead of summer, leveraging radio spots on Sydney and Melbourne stations, social media, digital marketing, and free skin check pop-ups. Australia has one of the highest melanoma rates globally, with two out of three Australians diagnosed with skin cancer before age 70 and one Australian dying from melanoma every six hours. OncoBeta's Rhenium-SCT skin cancer therapy using rhenium-188 isotope is now available at private clinics in Melbourne and Sydney as a non-invasive treatment option.PR NewswireGerman skin cancer patients join the EPIC-Skin studyOncoBeta GmbH announced that the University Clinic of Rostock in Germany has begun treating the first German patients with Rhenium-SCT as part of the international Phase IV EPIC-Skin clinical study for non-melanoma skin cancer. The study will follow approximately 210 adult patients across study centers in Australia, Austria, the United Kingdom, and Germany over 24 months to evaluate long-term efficacy, patient-reported outcomes, and quality of life. Rhenium-SCT is a non-invasive, single-session radioisotope therapy that treats skin cancer lesions without surgery or scarring, offering an alternative to standard surgical approaches.PR NewswireAvion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patientsAvion Medical Skin Centres (AMSC) has entered into an agreement with OncoBeta GmbH to offer the Rhenium-SCT treatment for non-melanoma skin cancer patients in Australia, with the first clinic opening at the Melbourne Theranostics Innovation Centre in Q3 2022. The treatment is a non-invasive, painless single-session alternative to traditional surgery that avoids scarring and loss of function. Australia has the highest incidence of non-melanoma skin cancer globally, with diagnosis rates continuing to rise annually.PR NewswireAustrian skin cancer patients take part in EPIC-Skin clinical studyOncoBeta GmbH announced that the first Austrian patients have been treated in the global phase IV EPIC-Skin clinical study evaluating the efficacy of Rhenium-SCT for treating non-melanoma skin cancer (NMSC). The international study will enroll 200 adult patients across study centers in Austria, Australia, Germany, and the United Kingdom, with patient follow-up periods up to 24 months. Rhenium-SCT is a single-session, non-invasive radioactive compound therapy that targets cancer cells directly without surgery, offering potential advantages over traditional surgical treatments that carry risks of scarring or loss of function.PR NewswireFirst Patients Registered Into OncoBeta's International Registry For Non-Melanoma Skin Cancer TreatmentsOncoBeta GmbH announced that the first patients have been registered into its world-first International Registry for Non-Melanoma Skin Cancer treatments, launched in November 2021 in partnership with Avion Medical. The registry will collect real-world patient data across three mainstay NMSC treatments to identify optimal treatment methods that can be applied internationally. An international committee of multi-disciplinary clinicians from South Africa, Australia, Italy, and Germany is leading the data collection effort, with participation by invitation only for physicians.PR NewswireOncoBeta receives ethics approval for EPIC-Skin study to evaluate Rhenium-SCT in AustraliaOncoBeta GmbH received ethics approval from Australia's National Health and Medical Research Council to begin a Phase IV clinical study evaluating its Rhenium-SCT therapy for non-melanoma skin cancer. The EPIC-Skin Study will enroll 210 patients across clinic sites in Austria, Germany, the United Kingdom, and five Australian cities, with first treatments scheduled at Royal North Shore Hospital in January 2022. The company has contracted Australian CRO Molecule2Market to conduct the international, multicentre study, which will assess Complete Response Rate, patient-reported outcomes, and quality of life over a 12-month participation period with up to 24 months of follow-up.PR NewswireOncoBeta initiates international EPIC-Skin study with Rhenium-SCT® for the treatment of Skin CancerOncoBeta GmbH has initiated the EPIC-Skin study, a phase IV international multi-centre trial evaluating the efficacy and patient-reported outcomes of its Rhenium-SCT® therapy for non-melanoma skin cancer. The study, conducted in collaboration with Australian CRO Molecule2Market, will enroll at least 175 patients across centers in Australia, Austria, Germany, and the United Kingdom starting in November 2021.